Balaxi Pharmaceuticals Limited (NSE:BALAXI)
India · Delayed Price · Currency is INR 24.51
+0.37 (1.53%)
Jul 30, 2026, 3:28 PM IST
Balaxi Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 14.17 | 250.7 | -23.87 | 459.63 | 476.58 |
Depreciation & Amortization | 21.53 | 18.95 | 20.98 | 17.53 | 5.12 |
Other Operating Activities | 189.83 | 59.21 | -55.21 | 51.48 | 19.4 |
Change in Accounts Receivable | -253.05 | -550.92 | -34.23 | -248.01 | 481.34 |
Change in Inventory | -49.99 | 36.87 | 228.55 | -63.2 | -850.86 |
Change in Accounts Payable | 50.3 | -128.6 | -54.81 | -158.07 | 274.07 |
Change in Other Net Operating Assets | -17.78 | -36.25 | -32.76 | 1.4 | -64.21 |
Operating Cash Flow | -45 | -350.03 | 48.66 | 60.75 | 341.45 |
Operating Cash Flow Growth | - | - | -19.90% | -82.21% | 1101335.48% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -369.25 | -211.19 | -6.93 | -130.58 | -53.21 |
Sale of Property, Plant & Equipment | 220.71 | - | 5.23 | - | - |
Cash Acquisitions | -59.26 | -6.45 | -8.77 | -19.22 | -220.23 |
Investment in Securities | - | - | - | - | 34.16 |
Other Investing Activities | - | - | -0 | 44.15 | -45.2 |
Investing Cash Flow | -207.79 | -217.64 | -10.46 | -105.65 | -284.48 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | - | - | - | 79.83 | - |
Long-Term Debt Issued | 41.66 | 339.63 | 60.4 | - | - |
Total Debt Issued | 41.66 | 339.63 | 60.4 | 79.83 | - |
Short-Term Debt Repaid | - | - | - | - | -0.21 |
Long-Term Debt Repaid | -1.03 | -0.98 | -0.94 | -0.89 | - |
Total Debt Repaid | -1.03 | -0.98 | -0.94 | -0.89 | -0.21 |
Net Debt Issued (Repaid) | 40.62 | 338.65 | 59.46 | 78.93 | -0.21 |
Issuance of Common Stock | - | 27.05 | 257.9 | 184.71 | - |
Common Dividends Paid | - | - | - | -4.98 | - |
Other Financing Activities | -36.22 | -26.93 | -14.83 | -3.54 | -1.42 |
Financing Cash Flow | 4.4 | 338.76 | 302.54 | 255.13 | -1.63 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | - | - | 0 | - | - |
Net Cash Flow | -248.39 | -228.91 | 340.74 | 210.22 | 55.33 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -414.24 | -561.23 | 41.74 | -69.83 | 288.23 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -15.33% | -19.18% | 1.73% | -2.08% | 10.32% |
Free Cash Flow Per Share | -7.60 | -10.17 | 0.81 | -1.38 | 5.76 |
Levered Free Cash Flow | -634.66 | -658.3 | 398.6 | -260.29 | 132.5 |
Unlevered Free Cash Flow | -610.26 | -639.96 | 409.08 | -257.16 | 133.39 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 37.43 | 27.78 | 15.26 | 3.54 | 1.42 |
Cash Income Tax Paid | 47.2 | 32.11 | 66.81 | 120.94 | 55.92 |
Change in Working Capital | -270.53 | -678.89 | 106.75 | -467.88 | -159.66 |